Codexis (CDXS)

• Market cap: $430M
• 1 day: 3.13%
• 5 days: -4.00%
• 1 month: 21.94%
• 3 months: 70.32%
• 6 months: 87.90%
• Year to date: 69.23%
• 1 year: 80.20%
• 5 years: -68.52%
• 10 years: 114.63%
• Sector: Materials
• Industry: Industrial Organic Chemicals

About: Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.

Employees: 174

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

38% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 32

11% more capital invested

Capital invested by funds: $175M [Q2] → $194M (+$19.3M) [Q3]

8.91% more ownership

Funds ownership: 79.79% [Q2] → 88.71% (+8.91%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

2% less funds holding

Funds holding: 118 [Q2] → 116 (-2) [Q3]

15% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 13

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $11 108% upside
• Avg. target: $11 108% upside
• High target: $11 108% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Kristen Kluska 38% 1-year accuracy 40 / 105 met price target

108% upside $11

Overweight Reiterated

22 Nov 2024